ANDA 207218, held by Sciegen Pharms. Clobetasol Propionate.
As of Nov 16, 2026, ANDA 207218 (Clobetasol Propionate), held by Sciegen Pharms, was first approved by FDA on Apr 28, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clobetasol Propionate0.05% ยท spray;topical | Clobetasol Propionate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters